Mutations in the gene encoding methyl-CpG-binding protein 2 cause Rett syndrome

Area of Science:

• Genetics
• Neuroscience
• Molecular Biology

Background:

• Rett syndrome is a rare X-linked dominant neurodevelopmental disorder primarily affecting girls.
• Approximately 80% of classic Rett syndrome cases are linked to mutations in the methyl-CpG-binding protein 2 (MECP2) gene.
• MeCP2 plays a crucial role in linking DNA methylation to transcriptional repression, essential for normal brain development.

Purpose of the Study:

• To investigate the functional consequences of MECP2 mutations in Rett syndrome.
• To explore the relationship between X-chromosome inactivation (XCI) patterns and disease severity in female carriers.
• To understand how different MECP2 mutations affect protein function and disease presentation.

Main Methods:

• Analysis of MECP2 gene mutations in Rett syndrome patients.
• Assessment of X-chromosome inactivation patterns in affected individuals and carriers.
• Evaluation of mutant mRNA stability in patients with truncating mutations.

Main Results:

• MECP2 mutations are the primary cause of Rett syndrome, leading to altered gene transcription during brain development.
• While most patients exhibit random XCI, skewed patterns are observed in some, particularly in asymptomatic or mildly affected female carriers.
• Non-random XCI patterns in some patients with truncating mutations suggest partial loss of MECP2 function and could attenuate disease effects.
• Mutant mRNA stability was observed in patients with truncating mutations, supporting the possibility of partial loss of function.

Conclusions:

• MECP2 mutations disrupt normal brain development in Rett syndrome.
• X-chromosome inactivation patterns significantly influence the clinical presentation and severity of Rett syndrome in female carriers.
• Further research is needed to fully elucidate the functional impact of various MECP2 mutations and their correlation with XCI patterns in Rett syndrome.